The global soft tissue repair market is expected to reach $14.7 billion in 2019 from $10.3 billion in 2014, at a CAGR of 7.5% during the forecast period of 2014 to 2019. Market growth will be attributed to innovative new product launches, the rising demand for treatment from the aging population, increasing healthcare expenditure, and the lack of substitutes.

The soft tissue repair market studied in this report is mainly segmented by products and applications. The market, by products, is segmented into tissue patch/mesh, soft tissue fixation devices, and laparoscopic instruments. On the basis of application the market is segmented into hernia repair, dural repair, vaginal sling procedure, skin repair, orthopedic repair, dental repair, and breast reconstruction repair.

Developed geographies like North America and Europe are saturated markets and expected to grow at a slower rate, whereas the Asian market is expected to witness the highest growth due to the increasing number of soft tissue repair surgical procedures (which is caused by the rising aging population and huge patient base).

The key players operating in this market are LifeCell Corporation (U.S.), Organogenesis (U.S.), C.R. Bard, Inc. (U.S.), Johnson & Johnson (U.S.), Covidien plc (Ireland), Arthrex, Inc. (U.S.), Smith & Nephew plc (U.K.), Integra Lifesciences Corporation (U.S.), Wright Medical Technology (U.S.), and Stryker Corporation (U.S.).